BR112018067597A2 - célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit - Google Patents

célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit

Info

Publication number
BR112018067597A2
BR112018067597A2 BR112018067597A BR112018067597A BR112018067597A2 BR 112018067597 A2 BR112018067597 A2 BR 112018067597A2 BR 112018067597 A BR112018067597 A BR 112018067597A BR 112018067597 A BR112018067597 A BR 112018067597A BR 112018067597 A2 BR112018067597 A2 BR 112018067597A2
Authority
BR
Brazil
Prior art keywords
cell
cell population
assessing
metabolism
toxicity
Prior art date
Application number
BR112018067597A
Other languages
English (en)
Other versions
BR112018067597A8 (pt
Inventor
Lombard Catherine
Dollet Pierre-Edouard
Sokal Etienne
Najimi Mustapha
Original Assignee
Université Catholique de Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Catholique de Louvain filed Critical Université Catholique de Louvain
Publication of BR112018067597A2 publication Critical patent/BR112018067597A2/pt
Publication of BR112018067597A8 publication Critical patent/BR112018067597A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

preparações de células progenitoras de fígado adulto (chamadas hhalpcs) têm sido fabricadas a partir de diferentes doadores humanos e caracterizadas pelo uso de marcadores de superfície celular que permitem identificar preparações de hhalpcs e/ou os métodos para produzir as mesmas que são mais adequados para terapia celular, em particular, para tratar doenças hepáticas ou disfunções de coagulação do sangue hereditárias.
BR112018067597A 2016-03-02 2017-03-02 célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit BR112018067597A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158327 2016-03-02
PCT/EP2017/054859 WO2017149059A1 (en) 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells

Publications (2)

Publication Number Publication Date
BR112018067597A2 true BR112018067597A2 (pt) 2019-01-08
BR112018067597A8 BR112018067597A8 (pt) 2019-10-15

Family

ID=55696855

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067597A BR112018067597A8 (pt) 2016-03-02 2017-03-02 célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit

Country Status (14)

Country Link
US (1) US20190046584A1 (pt)
EP (1) EP3423566A1 (pt)
JP (1) JP2019506890A (pt)
KR (1) KR20180114073A (pt)
CN (1) CN108779440A (pt)
AU (1) AU2017225825A1 (pt)
BR (1) BR112018067597A8 (pt)
CA (1) CA3013427A1 (pt)
EA (1) EA039743B1 (pt)
IL (1) IL261383A (pt)
MA (1) MA45274A (pt)
MX (1) MX2018010508A (pt)
SG (1) SG11201807041PA (pt)
WO (1) WO2017149059A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3016665T3 (da) 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
WO2020120666A1 (en) 2018-12-14 2020-06-18 Promethera Biosciences S.A./N.V. Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use
CA3122715A1 (en) 2018-12-14 2020-06-18 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing hla-e
TW202100171A (zh) 2019-03-26 2021-01-01 比利時商普羅米修亞生物科技股份有限公司 用於治療非酒精性脂肪肝疾病的成人肝臟前驅細胞
EP3947644A1 (en) * 2019-03-26 2022-02-09 Promethera Therapeutics Sa Adult liver progenitor cells for treating acute-on-chronic liver failure
PT3963050T (pt) 2019-04-30 2023-11-16 Cellaion Sa Preparação de células progenitoras alogénicas humanas derivadas de fígado
TW202106874A (zh) 2019-04-30 2021-02-16 比利時商普羅米修亞生物科技股份有限公司 人類同種異體肝衍生前驅細胞的製備(一)
KR20220081368A (ko) 2019-10-09 2022-06-15 셀라온 에스에이 혈관 과투과성을 특징으로 하는 장애에서 간 전구세포 또는 줄기세포, 이의 용해물 및/또는 조건화 배지의 사용
EP3881853A1 (en) 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
CN111778268B (zh) * 2020-06-03 2022-06-21 武汉仝干医疗科技股份有限公司 增强解毒功能基因片段及改造的HepG2细胞
WO2023180122A1 (en) 2022-03-24 2023-09-28 Université Catholique de Louvain Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
PL1969118T5 (pl) * 2005-12-21 2015-06-30 Univ Catholique Louvain Wyizolowane komórki macierzyste wątroby
CN101356264B (zh) * 2005-12-21 2014-05-14 鲁汶大学 分离的肝脏干细胞
EP2295537A4 (en) * 2008-05-14 2011-11-30 Public Univ Corp Yokohama City HUMAN HEPATIC STRAIN CELL, PREPARATION METHOD THEREFOR, METHOD OF INDUCING ITS DIFFERENTIATION AND METHOD OF USE
US8415149B2 (en) * 2010-05-06 2013-04-09 Gwo Xi Stem Cell Applied Technology Co., Ltd. Hepatic progenitor cells and uses thereof
EP2806879B1 (en) * 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
DK3016665T3 (da) * 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
AU2014314152B2 (en) * 2013-08-28 2020-02-06 Promethera Therapeutics Sa Method for producing adult liver progenitor cells

Also Published As

Publication number Publication date
MX2018010508A (es) 2018-11-09
JP2019506890A (ja) 2019-03-14
KR20180114073A (ko) 2018-10-17
EA039743B1 (ru) 2022-03-05
SG11201807041PA (en) 2018-09-27
IL261383A (en) 2018-10-31
EA201891913A1 (ru) 2019-02-28
BR112018067597A8 (pt) 2019-10-15
CA3013427A1 (en) 2017-09-08
CN108779440A (zh) 2018-11-09
US20190046584A1 (en) 2019-02-14
AU2017225825A1 (en) 2018-08-16
EP3423566A1 (en) 2019-01-09
MA45274A (fr) 2019-01-09
WO2017149059A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
BR112018067597A2 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
WO2020252397A8 (en) Small molecule proteolysis-targeting chimeras and methods of use thereof
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112022007612A2 (pt) Inibidores de raf quinases
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
CR20180200A (es) Ciano tienotriazolpirazinas y usos de las mismas
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
BR112019000201A2 (pt) compostos e seu uso na redução dos níveis de ácido úrico
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2712 DE 27-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.